Cucurbitane Triterpenoids Stimulate GLUT4 Translocation for Insulin Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes and obesity, such as thiazolidinediones and anti-obesity drugs, come with adverse effects like weight gain, gastrointestinal issues, and increased heart risk, while there is a need for safer and more effective insulin-sensitizing agents that can stimulate glucose uptake and improve insulin resistance.
Innovation Solution
Cucurbitane triterpenoids isolated from Momordica charantia L., which stimulate glucose uptake in muscle and adipose cells, promote the translocation of glucose transporter 4 (GLUT4) to the cell membrane, and activate adenosine monophosphate-activated protein kinase (AMPK), are used in pharmaceutical compositions for the prevention and treatment of diabetes and obesity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thiazolidinediones (TZDs) are used to treat diabetes by improving insulin resistance, then glucose uptake is improved, but weight gain and fluid retention occur as adverse effects
Solution Approach 1:
The patent extracts and isolates specific active compounds (cucurbitane triterpenoids including momordicosides) from Momordica charantia L. to create a purified pharmaceutical composition that targets insulin resistance without the adverse effects of conventional TZDs. This extraction principle separates the beneficial insulin-sensitizing activity from the harmful side effects associated with synthetic TZDs.
Solution Approach 2:
The patent utilizes natural plant compounds from Momordica charantia L. as a renewable, naturally-derived alternative to synthetic pharmaceuticals. These natural compounds provide the desired therapeutic effect without the long-term accumulation of harmful effects seen with conventional medications, offering a safer profile for chronic use.
2Object-generated harmful factors
If dimethyl biguanide is used to treat diabetes, then weight gain is avoided, but the drug mainly acts in liver rather than muscles reducing therapeutic satisfaction
Solution Approach 1:
The patent enhances the localized action of the pharmaceutical composition on muscle tissue by formulating specific cucurbitane triterpenoid compounds that demonstrate preferential activity in skeletal muscle. The composition is designed to target muscle glucose uptake specifically, improving insulin sensitivity at the desired site of action rather than systemic effects alone.
3Weight of moving object
If orlistat is used as an anti-obesity drug, then weight loss is achieved, but gastrointestinal adverse effects occur
Solution Approach 1:
The patent employs AMPK activation as an intermediary mechanism to achieve weight loss through increased energy expenditure and fat oxidation. Rather than directly inhibiting lipases like orlistat, the cucurbitane triterpenoid compounds activate AMPK, which mediates metabolic changes that result in weight loss without direct gastrointestinal irritation.
4Weight of moving object
If sibutramine is used as an anti-obesity drug, then weight loss is achieved, but blood pressure and heart rate increase
Solution Approach 1:
The patent utilizes the AMPK activation pathway to convert the goal of weight loss into a beneficial metabolic effect that does not carry cardiovascular risks. By activating AMPK, the composition promotes fat oxidation and energy expenditure in a way that achieves weight loss while avoiding the hypertension and tachycardia associated with sympathomimetic agents like sibutramine.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively increase glucose uptake and AMPK activity, potentially offering a safer and more effective treatment for diabetes and obesity without the adverse effects of existing medications.
Implementation Method 1
promote the translocation of the glucose transporter 4 (GLUT4) to the cell membrane
Implementation Method 2
increase the activity of adenosine monophosphate activated protein kinase (AMPK)
Data Source
AI summary
The present invention disclosed a medical use of cucurbitane triterpenoids represented by the following formula and isolated from Momordica charantia L. of Cucurbitaceae family in the preparation of medications for prevention and treatment of diabetes and obesity. The above cucurbitane triterpenoids may be acted as a glucose uptake stimulator, an agonist for the translocation of glucose transporter 4 (GLUT4) to the cell membrane, and an activator of adenosine monophosphate-activated protein kinase (AMPK). They may have potential for the prevention and treatment of diabetes and obesity.